Illumina, Inc. (ILMN)
Market Cap | 15.22B |
Revenue (ttm) | 4.28B |
Net Income (ttm) | 1.26B |
Shares Out | 153.77M |
EPS (ttm) | 7.91 |
PE Ratio | 12.51 |
Forward PE | 21.37 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,319,040 |
Open | 100.41 |
Previous Close | 99.50 |
Day's Range | 98.51 - 102.31 |
52-Week Range | 68.70 - 156.66 |
Beta | 1.40 |
Analysts | Hold |
Price Target | 120.29 (+21.55%) |
Earnings Date | Oct 30, 2025 |
About ILMN
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole... [Read more]
Financial Performance
In 2024, Illumina's revenue was $4.37 billion, a decrease of -2.93% compared to the previous year's $4.50 billion. Losses were -$1.22 billion, 5.34% more than in 2023.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for ILMN stock is "Hold." The 12-month stock price target is $120.29, which is an increase of 21.55% from the latest price.
News

Illumina: Innovation Outweighs Short-Term Risks - A Long-Term Buy Ahead Of Q3 Earnings
Illumina is at a pivotal moment, balancing near-term challenges with innovations in multiomics, AI, and proteomics to redefine its growth trajectory. ILMN's planned SomaLogic acquisition and new AI-dr...
Final Trades: Illumina, Columbia Banking, Alibaba and JPMorgan Chase
The Investment Committee give you their top stocks to watch for the second half.

Illumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights
At ASHG, an early access customer from the London Health Sciences Center Research Institute will demonstrate the power of the 5-base genome for accelerating resolution of rare disease cases Proprietar...

Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot
Illumina's up-and-coming constellation innovation delivers accuracy, speed, and ease of use in trial by GeneDx Constellation outperformed orthogonal methods in identifying select difficult-to-map vari...

Illumina to Announce Third Quarter 2025 Financial Results on Thursday, October 30, 2025
SAN DIEGO , Oct. 14, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the third quarter 2025 following the close of market on Thursday, October 30, 202...

Illumina launches new business to accelerate technology and data-driven discovery
New business focuses on developing data assets, software, and AI to fuel life science breakthroughs Expands pharma access to large omics datasets to advance target discovery and drug development SAN D...

ILMN Stock vs. IQV Stock
Amid increased competition from China's MGI Tech, Illumina's stock (NASDAQ: ILMN) has dropped by 11% in a week. MGI Tech's DNA sequencers are reportedly gaining market share, and despite a recent decl...

Illumina advances personalized cancer care with new pharma development partnerships
Illumina and pharma partners will develop companion diagnostics for historically important KRAS biomarker SAN DIEGO , Sept. 23, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) will partner with mult...

Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine
Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines Members leverage AI-powered dataset to accelerate pharma R&D...

Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development
Illumina Protein Prep can measure 9500 unique human protein targets, offering new insights into protein biology to fuel novel discovery for treatment of disease Following early access program, custome...

mRNA Biotechs - Long-Term Value Risks Abound
mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery c...

Illumina: The Stock Is Still Undervalued
Illumina exceeded Q2FY25 expectations and raised FY25 guidance, driven by resilient Chinese operations and strong clinical market growth, especially in oncology. The company is expanding into proteomi...

These Analysts Boost Their Forecasts On Illumina Following Upbeat Results
Illumina, Inc. ILMN reported better-than-expected earnings for the second quarter on Thursday.

Illumina, Inc. (ILMN) Q2 2025 Earnings Call Transcript
Illumina, Inc. (NASDAQ:ILMN) Q2 2025 Earnings Conference Call July 31, 2025 4:30 PM ET Company Participants Ankur Dhingra - Chief Financial Officer Brian Blanchett - VP of Finance & Treasurer and Int...

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2025
Revenue of $1.06 billion for Q2 2025, down 3% from Q2 2024 on both a reported and constant currency basis GAAP operating margin of 20.2% and non-GAAP operating margin of 23.8% for Q2 2025 GAAP diluted...

Illumina enhances flagship assay to accelerate access to comprehensive tumor profiling
Illumina TruSight™ Oncology 500 v2 research assay is now available with built-in HRD biomarker detection, faster turnaround time, and lower tissue sample input Illumina's growing research and clinical...

Illumina Stock: What Went Wrong And Why It's Best To Stay Away
Illumina Inc. ILMN is currently in Phase 17 of its 18-phase Adhishthana Cycle on the weekly chart. A detailed structural analysis using the Adhishthana Principles reveals deeper issues that go beyond ...

Illumina: Higher Profit Margin Despite GRAIL Divestiture And Macroeconomic Headwinds
With Illumina's divestiture of GRAIL, the company will improve its operating expenses, since GRAIL reported significant losses while it was part of Illumina. The global DNA sequencing market is expect...

Illumina to Announce Second Quarter 2025 Financial Results on Thursday, July 31, 2025
SAN DIEGO , July 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the second quarter 2025 following the close of market on Thursday, July 31, 2025....

Illumina named to TIME's World's Most Sustainable Companies list for the second consecutive year
Illumina was also recognized as one of the Best Companies to Work For byU.S. News & World Report SAN DIEGO , July 10, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced two awards recog...

Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy
Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach Positions Illumina to achieve growth in a large, expanding market Illumin...

Infinity Bio Closes $8M Series A Financing Led by Illumina Ventures to Expand Leadership in Antibody Reactome Profiling
BALTIMORE--(BUSINESS WIRE)--Infinity Bio, a biotechnology company pioneering technologies to map immune responses at scale, today announced the successful closing of an $8 million Series A financing r...

lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics
SAN DIEGO , June 10, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), aligned with its commitments to advance the power of genomics, today published its annual Corporate Social Responsibility (CSR) ...

Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis
New AI algorithm accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome at scale for the first time SAN DIEGO , May 29, 2025 /PRNewswire/ -- Illumina ...

Illumina, Inc. (ILMN) Bernstein 41st Annual Strategic Decisions Conference (Transcript)
Illumina, Inc. (NASDAQ:ILMN) Bernstein 41st Annual Strategic Decisions Conference Call May 28, 2025 2:30 PM ET Company Participants Jacob Thaysen - Chief Executive Officer Conference Call Participant...